November 18, 2020
Pfizer’s, Biontech’s Covid-19 vaccine candidate meets endpints in P3 trial
Pfizer’s and Biontech’s vaccine candidate for COVID-19 has met all the study’s primary efficacy endpoints.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: BioNTech
November 9, 2020
Pfizer says its Covid-19 vaccine 90% effective
Pfizer says its vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
May 5, 2020
Pfizer, BioNTech in first doses in U.S. in global COVID-19 vaccine making
First participants have been dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.
March 16, 2020
BioNTech, Fosun Pharma, Pfizer working on COVID-19 vaccine. Clinical testing in Germany in April
BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.
July 10, 2019
BioNTech Raises $325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline
BioNTech pulled one of the largest private EU biotech funding events expands global shareholder base with $325 from investors
November 3, 2015
Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement
Sanofi and BioNTech A.G. have entered into a multiyear exclusive collaboration and license agreement.